Wednesday, November 28, 2012

Rare Trade Setup Could Deliver Blockbuster Returns From This Tiny Biotech

Wall Street legend, Peter Lynch, once said, "During the Gold Rush, most would-be miners lost money, but people who sold them picks, shovels, tents and blue-jeans (Levi Strauss) made a nice profit."

Today, I want to review a microcap company that could be a modern-day investment in this business model with a chart that presents a solid trading opportunity.


Companies that sell consumables, products that are completely used up and then need to be repurchased, can enjoy steady sales and earnings, even if some of their buyers go bust. Finding undervalued companies that supply critical inputs to an industry can be a way to identify trading candidates.

In the drug industry, biologics are among the best-selling drugs in the world. These drugs are made from living organisms and are more complex than chemically synthesized drugs, the more common type of pharmaceutical drugs. Biologics are used in the treatment of rheumatoid arthritis and several types of cancer. Research and development is under way to find other blockbuster biological drugs, but that process is expensive. According to one research report, it can cost $1.2 billion and take 10 to 15 years to get a drug through the regulatory process.  (more)

No comments:

Post a Comment